Gamified occupational therapy for adolescents with Duchenne muscular dystrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to enhance the quality of life and emotional health of adolescents with Duchenne muscular dystrophy through a gamified occupational therapy program, comparing its effectiveness to traditional occupational therapy. The study will assess improvements in occupational performance and satisfaction among participants. By utilizing engaging and interactive methods, the goal is to develop innovative rehabilitation strategies tailored for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Being diagnosed with Duchenne muscular dystrophy
* To be literate in Turkish
* To have scored 27 points or more on the Modified Mini Mental Test
* Having a computer, tablet and internet connection
* Volunteering to participate in the study by their parents and reading and signing the informed consent form

Exclusion Criteria:

* Having a neurological disease other than Duchenne muscular dystrophy and/or another diagnosed neurological disease accompanying Duchenne muscular dystrophy
* Having a cooperation problem that prevents completing the assessments for any reason
* Difficulty understanding and speaking the Turkish language

Where it's running

• Lokman Hekim University
  Ankara, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Başak Çağla Arslan, Master Degree
• Email: ptbasakc@gmail.com
• Phone: 4448548

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VM100: a nutritional supplement to see if it improves quality of life for boys with Duchenne

  This Phase 2 study tests VM100, a nutritional drink, in boys aged 8 and up with Duchenne muscular dystrophy to see if it can improve quality of life and reduce fatigue.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT07766980

• KER-065 for Duchenne Muscular Dystrophy: safety and potential benefit in boys and men

  This study tests whether KER-065 is safe and can help with symptoms in males with Duchenne muscular dystrophy, including both ambulatory and nonambulatory participants who are on standard care.

  Recruiting at 2 sites Phase 2 Keros Therapeutics, Inc. · Tbilisi and 3 other locations · NCT07704099

• GNR-097 gene therapy for Duchenne muscular dystrophy in boys

  This study tests a gene therapy (GNR-097) to see if it is safe, tolerable, and potentially beneficial for ambulatory boys with Duchenne muscular dystrophy.

  Recruiting at 6 sites Phase 1/2 Ao Generium · Minsk and 5 other locations · NCT07673809

• ELEVIDYS safety in Duchenne patients treated after market approval

  This study tests the safety of ELEVIDYS, with sirolimus as a protective treatment, in male children and young adults with Duchenne Muscular Dystrophy who have previously received ELEVIDYS or are eligible to receive it commercially.

  Recruiting Phase 4 Sarepta Therapeutics, Inc. · Houston, Texas · NCT07542314

• Clinical skills teaching video library for occupational therapy

  This project will create a secure video and audio library of clinical teaching sessions for occupational therapists, trainees, and adult patients or family members to support learning.

  Recruiting Chang Gung Memorial Hospital · Kaohsiung City, Niaosong Dis · NCT07501936

• Gamified metaverse training to teach nursing students pressure ulcer care

  This project tests whether a gamified metaverse training helps second-year nursing students feel more confident and learn to prevent and manage pressure ulcers.

  Recruiting Baskent University · Ankara, Ankara · NCT07395284

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.